421 related articles for article (PubMed ID: 24750367)
21. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V
Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441
[TBL] [Abstract][Full Text] [Related]
22. Novel agents for the treatment of Hodgkin lymphoma.
Dumaswala K; Mehta A
Expert Rev Hematol; 2015 Oct; 8(5):659-67. PubMed ID: 26343891
[TBL] [Abstract][Full Text] [Related]
23. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
[TBL] [Abstract][Full Text] [Related]
24. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Diehl V; Fuchs M;
Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
[TBL] [Abstract][Full Text] [Related]
25. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.
von Tresckow B; Plütschow A; Fuchs M; Klimm B; Markova J; Lohri A; Kral Z; Greil R; Topp MS; Meissner J; Zijlstra JM; Soekler M; Stein H; Eich HT; Mueller RP; Diehl V; Borchmann P; Engert A
J Clin Oncol; 2012 Mar; 30(9):907-13. PubMed ID: 22271480
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy for the treatment of Hodgkin lymphoma.
Donato EM; Fernández-Zarzoso M; De La Rubia J
Expert Rev Hematol; 2017 May; 10(5):417-423. PubMed ID: 28359170
[TBL] [Abstract][Full Text] [Related]
27. Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
Alperovich A; Younes A
Cancer J; 2016; 22(1):23-6. PubMed ID: 26841013
[TBL] [Abstract][Full Text] [Related]
28. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.
Oak E; Bartlett NL
Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729
[TBL] [Abstract][Full Text] [Related]
29. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
[TBL] [Abstract][Full Text] [Related]
30. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
[TBL] [Abstract][Full Text] [Related]
31. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
[TBL] [Abstract][Full Text] [Related]
32. Anti-CD30 Antibodies for Hodgkin lymphoma.
Foyil KV; Bartlett NL
Curr Hematol Malig Rep; 2010 Jul; 5(3):140-7. PubMed ID: 20446121
[TBL] [Abstract][Full Text] [Related]
33. Induction therapy for advanced-stage Hodgkin lymphoma: late intensification (ABVD chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant only for those who relapse).
Ansell SM
Hematol Oncol Clin North Am; 2014 Feb; 28(1):75-86. PubMed ID: 24287069
[TBL] [Abstract][Full Text] [Related]
34. Managing Risk in Hodgkin Lymphoma.
Armitage JO; Chen RW; Moskowitz CH; Sweetenham J
Clin Adv Hematol Oncol; 2015 Feb; 13(2 Suppl 1):1-19. PubMed ID: 26430791
[TBL] [Abstract][Full Text] [Related]
35. Brentuximab vedotin in Hodgkin's lymphoma.
Pro B; Perini GF
Expert Opin Biol Ther; 2012 Oct; 12(10):1415-21. PubMed ID: 22937794
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of antibody-drug conjugate brentuximab vedotin in treating Hodgkin's lymphoma.
Viviani S; Guidetti A
Expert Opin Biol Ther; 2018 Aug; 18(8):841-849. PubMed ID: 29999431
[TBL] [Abstract][Full Text] [Related]
37. Brentuximab vedotin for treating Hodgkin's lymphoma: an analysis of pharmacology and clinical efficacy.
Illés Á; Jóna Á; Miltényi Z
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):451-9. PubMed ID: 25642958
[TBL] [Abstract][Full Text] [Related]
38. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
[TBL] [Abstract][Full Text] [Related]
39. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
[TBL] [Abstract][Full Text] [Related]
40. The past: what we have learned in the last decade.
Borchmann P; Engert A
Hematology Am Soc Hematol Educ Program; 2010; 2010():101-7. PubMed ID: 21239778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
